The most likely clinical setting for the use of EGFR inhibitors is as an adjunct therapy to antibiotic use in treatment of mucosal infections such as mTSS, non-menstrual TSS or pneumonia through systemic administration. This evidence concerns the gene EGFR and susceptibility to pneumonia measurement.